$AMRS Fully diluted, they are only valued at $750M. And they are going to do, at the very least, $150M in revenue again this year. That is only a 5x multiple... - Biossance - Pipette - Apprinova - Purecane - AB Mauri - Patchouli - Vanilla - Sandalwood - Rose Inc. - IDRI - Squalene - Monoclonal Antibody platform - Novvi - DoD/BR-1 - Ethanol - Cannabinoids - HMOs - Yifan - Plant Protein Development (Impossible burger type) - Sweetener development If you don't think this is a $1B company, I'd love to know why. Cash burn? Debt? Margin? The molecule development platform alone is worth $1B at the very least. Look at TWST. If Amyris sold off, licensed, or went to a royalty only structure on all of the above items, they would easily raise $700M (an extremely conservative estimate), enough to pay off all liabilities and have $500M in cash as a molecule development platform alone. They just raised $200M 5 months ago at $3, essentially a $1B FD valuation. Remember that. Keep perspective.